NEW FEATURE

Selective Estrogen Receptor Degrader (SERD) Benefit Predictor

Available for patients with breast cancer

GUARDANT360 Liquid CDx | GUARDANT360 Liquid

Powered by INFINITY AI

THE CLINICAL CHALLENGE

Resistance to aromatase inhibitors (AIs) in HR+ metastatic breast cancer is common and is frequently driven by *ESR1* mutations.[1] SERDs can provide clinical benefit in this setting, with ESR1 mutations serving as established biomarkers to help guide the transition from AI to SERD-based endocrine therapy.[1,2]

However, no validated biomarker currently exists to help guide SERD use in *ESR1*-wild-type (*ESR1*-wt) patients. Identifying which *ESR1-wt* patients may benefit from SERD therapy, specifically fulvestrant, could help inform treatment selection.[3]


AN EPIGENOMIC APPROACH TO HELP PREDICTING SERD (FULVESTRANT) BENEFIT

Guardant360® Liquid CDx* powered by InfinityAI evaluates epigenomic signals to generate a novel SERD response predictor designed to predict the likelihood of benefit from SERD therapy, based on data from patients treated with fulvestrant. The predictor was validated in a real-world cohort of patients with *ESR1*-wt disease who had progressed on prior endocrine therapy.[1]

IDENTIFYING PATIENTS MORE LIKELY TO BENEFIT FROM FULVESTRANT


Among patients predicted to have high SERD benefit, those treated with fulvestrant had longer TTD than those treated with chemotherapy, whereas this difference was not observed among patients predicted to have low SERD benefit.[3]

Patients predicted to have high SERD benefit



At risk						
SERD (n=186)	186	109	45	20	3	0
Chemotherapy (n=114)	114	58	15	5	3	0

Patients predicted to have low SERD benefit



At risk						
SERD (n=104)	104	59	27	12	2	
Chemotherapy (n=99)	99	49	18	5	1	

*Offered as professional services only.

InfinityAI is not a standalone customer product. "Powered by InfinityAI" refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Important Note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

NEW FEATURE


Selective Estrogen Receptor Degrader (SERD) Benefit Predictor

Available for patients with breast cancer

GUARDANT360 Liquid CDx | GUARDANT360 Liquid

Powered by INFINITY AI

REPORT EXAMPLE



The SERD therapy predictor was validated in HR+ patients without ESR1 mutations with the aim of finding ESR1-wildtype patients who can benefit from SERD therapy. The marker's position relative to the threshold indicates likelihood of benefit.

Get more insight into potential ICI monotherapy benefit with Guardant360® Liquid CDx†

†Offered as professional services only.

References: 1. Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714-3728. doi:10.1002/cncr.32345. **2.** Burstein HJ, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, HER2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2024. **3.** Zhang S, Zhang N, Ramani V, et al. DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer. Cancer Res. 2026;86(7 suppl):2279. doi:10.1158/1538-7445.AM2026-2279.

InfinityAI is not a standalone customer product. "Powered by InfinityAI" refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Important Note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

ONC-US-00687 Copyright © 2026 Guardant Health, Inc. All rights reserved

GUARDANT®